1511 A review of the aetiology of squamous cell carcinoma of the conjunctiva
R Newton

Experimental Oncology
1514 Allele loss occurs frequently at hMLH1, but rarely at hMSH2, in sporadic colorectal cancers with microsatellite instability
IPM Tomlinson, M Ilyas and WF Bodner

1518 Expression of the zinc finger gene EVI-1 in ovarian and other cancers
DJ Brooks, S Woodward, FH Thompson, B Dos Santos, M Russell, J-M Yang, Y-X Guan, J Trent, D Alberts and R Taele

1526 Photodynamic therapy using intravenous δ-aminolaevulinic acid-induced protoporphyrin IX sensitisation in experimental hepatic tumours in rats
K Svanberg, DL Liu, I Wang, S Andersson-Engels, U Stenram and S Svanberg

1534 High levels of MDM2 are not correlated with the presence of wild-type p53 in human malignant mesothelioma cell lines
S Ungar, A Van de Meeren, L Tammilehto, K Linnaimaa, K Mattson and BI Gerwin

1541 Aromatase cytochrome P450 gene expression in endometrial carcinoma
H Sasano, K Kaga, S Sato, A Yajima, H Nagura and N Harada

1545 Anthracycline antibiotics non-covalently incorporated into the block copolymer micelles: in vivo evaluation of anti-cancer activity
EV Batrakova, TY Dorodnych, EY Klinskii, EN Klushnenkova, OB Shemchukova, ON Goncharova, SA Arjakov, VY Alakhov and AV Kabanov

1553 Modulation of sensitivity to cis-diaminedichloroplatinum (II) by thromboxane A2, receptor antagonists in non-small-cell lung cancer cell lines
K Kasahara, M Fujimura, T Bando, K Shibata, H Shirasaki and T Matsuda

1559 Oxygen tension and vascular density in human cervix carcinoma
H Lyng, K Sundfer, C Tropé and EK Rofstad

1564 Therapy of murine mammary carcinoma metastasis with interferon γ and MHC gene-transduced tumour cells
P Nanni, C De Giovanni, L Landuzzi, G Nicoletti, F Frabetti, I Rosi, F Cavallo, M Giovarelli, G Forni and P-L Lollini

1570 Combination toxicity of etoposide (VP-16) and photosensitisation with a water-soluble aluminium phthalocyanine in K562 human leukaemic cells
TG Gantchev, N Brasseur and JE van Lier

1578 Mutation of the TP53 gene and allelic imbalance at chromosome 17p13 in ductal carcinoma in situ
KE Munn, RA Walker, L Menasce and JM Varley

1586 Expression and structural features of endoglin (CD105), a transforming growth factor β1 and β3 binding protein, in human melanoma
M Altomonte, R Montagner, E Fonsatti, F Colizzi, I Cattarossi, I Brasoveanu, R Nicotra, A Cattelan, PG Natali and M Maio

1592 Allele loss from large regions of chromosome 17 is common only in certain histological subtypes of ovarian carcinomas
J Papp, B Csokay, P Bosze, Z Zalay, J Toth, B Ponder and E Olah

1598 Fibronectin promotes the proliferation of cytotoxic T lymphocytes generated from cancer patients
S Mizobata, H Tanimura, H Yamaue, M Tani, T Tsunoda, M Iwahashi, K Noguchi, N Nishimoto, T Hotta and K Ariti

1605 Chromophilic renal cell carcinoma: cytomorphological and cytogenetic characterisation of four permanent cell lines
C-D Gerharz, B Hildebrandt, R Moll, U Ramp, M Sarbia, S Störkel, P Koldovsky and HE Gabbert

Clinical Oncology/Epidemiology
1615 Allelic loss at chromosome 13q12-q13 is associated with poor prognosis in familial and sporadic breast cancer
J van den Berg, O Johannsson, S Håkansson, H Olsson and A Borg

1620 An increased NM23H1 copy number may be a poor prognostic factor independent of LOH on 1p in neuroblastomas
O Takeda, M Handa, T Uehara, N Maseki, A Sakahita, M Sakurai, N Kanda, Y Arai and Y Kaneko
1627 Loss of interleukin 4 receptor-associated molecule gp200-MR6 in human breast cancer: prognostic significance
L Kaklamanis, MI Koukourakis, R Leek, AGiatromanolaki, M Ritter, R Whitehouse, KC Gatter and AL Harris

1632 Analysis of polypeptide expression in benign and malignant human breast lesions: down-regulation of cytokeratins
B Franzén, S Linder, AA Alaiya, E Eriksson, K Uruy, T Hirano, K Okuzawa and G Auer

1639 Keratin 19 mRNA measurement to detect micrometastases in lymph nodes in breast cancer patients
A Schoenfeld, Y Luqmani, HD Sinnett, S Shousha and RC Coombes

1643 A comparison of axillary node status between cancers detected at the prevalence and first incidence breast screening rounds
PA Holland, J Walls, CRM Boggis, FKnox, AD Baildam and NJ Bundred

1647 A clinicopathological study of asymptomatic gastric cancer
A Matsukuma, M Furusawa, H Tomoda and Y Seo

1651 Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer
AA Melcher, D Mort and TS Maughan

1655 Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy
SD Foss, C Sternberg, HI Scher, CH Theodore, BMead, D Dearnaley, JT Roberts and ESkovlund

1660 Initial prognostic factors in small-cell lung cancer patients predicting quality of life during chemotherapy
J Bernhard, C Hünry, M Bacchi, RA Joss, FCavalli, H-J Senn, S Leyvraz, R Stahel, CLudwig and P Alberto for the Swiss Group for Clinical Cancer Research (SAKK)

1668 Effective treatment of advanced breast cancer with vinorelbine, mitomycin C plus human granulocyte colony-stimulating factor
GV Kornek, K Haider, WKwasny, MHejna, MRaderer, SGmehdadi, D Burger, BSchneewiess, DDeptich and WScheithauer

1674 What do cancer patients mean when they complain of concentration and memory problems?
ACull, C Hay, SB Love, MMackie, ESmet and M Stewart

1680 Cancer mortality in French Polynesia between 1984 and 1992
F de Vathaire and B Le Vu

1682 Case-control study of risk factors for prostate cancer
MIlić, HVlajinac and JMarinkovic

1687 Trends in eye cancer mortality among adults in the USA and England and Wales
AJEFoss and PJDolin

1690 Book reviews

1691 Erratum

The contents page of this journal is now available on the Internet before publication at: http://www.stockton-press.co.uk